

Daiichi Sankyo Provides Update on Ongoing FDA Review for Quizartinib for Treatment of Patients with Relapsed/Refractory *FLT3*-ITD AML

Tokyo and Basking Ridge, NJ – (April 4, 2019) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) of quizartinib, an investigational *FLT3* inhibitor, currently under Priority Review for the treatment of adult patients with relapsed/refractory *FLT3*-ITD acute myeloid leukemia (AML). The new Prescription Drug User Fee Act (PDUFA) action date is August 25, 2019.

The FDA extended the action date by three months to allow time to review additional data submitted by Daiichi Sankyo in association with an FDA request.

“We look forward to continued dialogue with the FDA throughout the review process of quizartinib,” said Arnaud Lesegretain, Vice President, Oncology Research and Development and Head, AML Franchise, Daiichi Sankyo. “We remain confident in the data supporting our NDA submission and are committed to bringing quizartinib forward as a potential treatment for relapsed or refractory *FLT3*-ITD AML, a particularly aggressive and difficult-to-treat subtype of AML, where patients need additional targeted treatment options.”

About Quizartinib

Quizartinib, the lead investigational agent in the investigational AML Franchise of the Daiichi Sankyo Cancer Enterprise, is an oral selective type II *FLT3* inhibitor currently under regulatory review with the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Japan Ministry of Health, Labour and Welfare (MHLW) for the treatment of adult patients with relapsed/refractory AML, which is *FLT3*-ITD positive.

Regulatory submissions in the U.S., EU and Japan are based on the results of the pivotal phase 3 QuANTUM-R study of quizartinib, which was the first randomized phase 3 study to show that a *FLT3* inhibitor prolonged overall survival as an oral, single agent compared to chemotherapy in patients with relapsed/refractory *FLT3*-ITD AML. Topline results of the phase 3 QuANTUM-R study were presented during the plenary program at the 23rd Congress of the European Hematology Association in June 2018, and comprehensive analyses were presented during an oral presentation at the 60th Annual Meeting of the American Society of Hematology in December 2018.

In the QuANTUM-R study, the median treatment duration with quizartinib was 4 cycles of 28 days each versus 1 cycle in the salvage chemotherapy arm. Incidence of treatment-emergent adverse events was comparable between patients who received single agent quizartinib and those who received salvage chemotherapy. The most common adverse drug reactions (>30 percent, any Grade) in patients treated with quizartinib included infections, bleeding, nausea, asthenic conditions, pyrexia, febrile neutropenia and vomiting, and the most common Grade ≥ 3 adverse drug reactions (>20 percent) were infection and febrile neutropenia. The most common laboratory adverse reactions (incidence >50 percent) were decreased white blood cell count, decreased lymphocyte count, decreased hemoglobin, decreased neutrophil count and decreased platelet count. The safety profile observed in QuANTUM-R appears consistent with that observed at similar doses in the quizartinib clinical development program.

Quizartinib also is in phase 3 development for newly-diagnosed *FLT3*-ITD AML ([QuANTUM-First](#)) in the U.S., EU and Japan and in phase 1 development in combination with an investigational MDM2 inhibitor, milademetan, for relapsed/refractory *FLT3*-ITD AML and newly-diagnosed *FLT3*-ITD AML unfit for intensive chemotherapy in the U.S., EU and Japan.

Quizartinib is an investigational agent that has not been approved for any indication in any country. Safety and efficacy have not been established.

About *FLT3*-ITD Acute Myeloid Leukemia

AML is an aggressive blood and bone marrow cancer that causes uncontrolled growth and accumulation of malignant white blood cells that fail to function normally and interfere with the production of normal blood cells.¹ In the U.S. this year, it is estimated that there will be more than 19,000 new diagnoses of AML and more than 10,000 deaths from AML.² The five-year survival rate of AML reported from 2005 to 2011 was approximately 26 percent, which was the lowest of all leukemias.¹

FLT3 gene mutations are one of the most common genetic abnormalities in AML.³ *FLT3*-ITD is the most common *FLT3* mutation, affecting approximately one in four patients with AML.^{4,5,6,7} *FLT3*-ITD is a driver mutation that presents with high leukemic burden and has poor prognosis and a significant impact on disease management for patients with AML.^{5,8}

Patients with *FLT3*-ITD AML have a worse overall prognosis, including an increased incidence of relapse, an increased risk of death following relapse, and a higher likelihood of relapse following hematopoietic stem cell transplantation, as compared to those without this mutation.^{9,10}

About Daiichi Sankyo Cancer Enterprise

The mission of Daiichi Sankyo Cancer Enterprise is to leverage our world-class, innovative science and push beyond traditional thinking to create meaningful treatments for patients with cancer. We are dedicated to transforming science into value for patients, and this sense of obligation informs everything we do. Anchored by three pillars including our investigational Antibody Drug Conjugate Franchise, Acute Myeloid Leukemia Franchise and Breakthrough Science, we aim to deliver seven distinct new molecular entities over eight years during 2018 to 2025. Our powerful research engines include two laboratories for biologic/immuno-oncology and small molecules in Japan, and Plexxikon Inc., our small molecule structure-guided R&D center in Berkeley, CA. Compounds in pivotal stage development include: [fam-] trastuzumab deruxtecan, an antibody drug conjugate (ADC) for HER2 expressing breast, gastric and other cancers; quizartinib, an oral selective *FLT3* inhibitor, for newly-diagnosed and relapsed/refractory *FLT3*-ITD acute myeloid leukemia (AML); and pexidartinib, an oral CSF1R inhibitor, for tenosynovial giant cell tumor (TGCT). For more information, please visit:

www.DSCancerEnterprise.com.

About Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group's 2025 Vision to become a "Global Pharma Innovator with Competitive Advantage in Oncology," Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases. For more information, please visit: www.daiichisankyo.com.

Contact:

Jennifer Brennan

Daiichi Sankyo, Inc.

jbrennan2@dsi.com

+1 908 992 6631 (office)

+1 201 709 9309 (mobile)

References

- ¹ Leukemia & Lymphoma Society. Facts 2015-2016. 2016.
- ² American Cancer Society. Key Statistics for AML. 2018
- ³ Small D. Am Soc Hematol Educ Program. 2006;178-184
- ⁴ Schneider F, et al. Ann Hematol. 2012;91:9-18.
- ⁵ Santos FPS, et al. Cancer. 2011;117(10):2145-2155
- ⁶ Kainz B, et al. Hematol J. 2002;3:283-289
- ⁷ Kottaridis PD, et al. Blood. 2001;98(6):1752-1759
- ⁸ Zarrinkar P, et al. Blood. 2009;114(14):2984-2992.
- ⁹ Wagner K, et al. Haematol. 2011;96(5):681-686.
- ¹⁰ Brunet S, et al. J Clin Onc. 2012;30(7):735-741.